Retatrutide (5 mg) is a triple-agonist peptide evaluated for its activity on GLP-1, GIP, and glucagon receptors. This receptor combination is explored in metabolic research focused on energy balance, appetite regulation, and glycaemic control. EU Pharmaceuticals supplies high-purity lyophilized Retatrutide (5 mg) for reference and educational use in peptide and metabolic signaling studies.

Key Research Features

• Triple-pathway receptor model: GLP-1R, GIPR, and GCGR engagement.
• Metabolic focus: Investigated for appetite, energy expenditure, and glucose regulation.
• Weekly reference cadence: Enables extended receptor-response monitoring.
• Titration-friendly: Allows gradual dose escalation to evaluate tolerance and receptor sensitivity.

Product Specifications

• Compound: Retatrutide (LY3437943)
• Form: Lyophilized peptide powder
• Content: 5 mg per vial

Research Overview

Retatrutide has been studied as a multi-receptor agonist model combining GLP-1, GIP, and glucagon receptor activation. Publications note its potential for supporting energy expenditure, appetite control, and improved metabolic markers through overlapping endocrine pathways. Its long-acting structure makes it suitable for once-weekly reference intervals in peptide-based metabolic research.

Reference Sampling & Handling

• Reconstitution Option 1: Add 2 mL bacteriostatic water → 2.5 mg/mL
• Reconstitution Option 2: Add 1 mL bacteriostatic water → 5 mg/mL
• Introduce diluent slowly down the vial wall and gently swirl to dissolve (avoid shaking).
• Storage: Lyophilized at −20 °C (dry & dark); after reconstitution, refrigerate at 2–8 °C for ≤ 30 days.

Reference Sampling Protocol (2 mL → 2.5 mg/mL)

Alternative Sampling (1 mL → 5 mg/mL)

1 unit = 0.01 mL. At 2.5 mg/mL, 1 unit ≈ 0.025 mg; at 5 mg/mL, 1 unit ≈ 0.05 mg.

Reference Frequency & Safety Notes

• Observation interval: One sample every 7 days (weekly) recommended for steady data capture.
• Titration: Gradually increase sampling mass no faster than every 4 weeks to monitor tolerance.
• Upper reference limit: ≤ 5 mg per 7-day cycle for standard assay models.
• Washout period: ≥ 7 days between samples for consistent receptor reset data.
• Observed tolerability (literature): Mild GI disturbance, transient nausea, or fatigue in dose-escalation models.

Intervals and limits reflect Retatrutide Phase I–II data and are provided for educational reference only.

Mechanism of Action (Research Summary)

• GLP-1 Receptor: Delays gastric emptying and supports satiety response models.
• GIP Receptor: Modulates insulin and energy utilization pathways.
• Glucagon Receptor: Enhances energy expenditure and fat-oxidation studies.
• Combined agonism offers a holistic view of metabolic signal integration.

What’s in the Box

• 1 × Retatrutide 5 mg lyophilized vial
• 1 × 2 mL bacteriostatic water for reconstitution

Why Choose EU Pharmaceuticals?

EU Pharmaceuticals supplies peptides manufactured under strict analytical verification for purity, identity, and stability. Each lot is validated for consistent mass spectrometry and HPLC profiles to ensure reliable research results.

For laboratory, educational, and research use only. Not for human or veterinary ingestion or therapeutic application. No medical or performance claims are made or implied. Buyer assumes responsibility for lawful handling and regulatory compliance.